Sağlık Sitelerinden Haberler


        
 
Bilgi:
Etiketler:
Yazarın adı:
Yazarın soyadı:


EklenmeTarihi: 20 Kasım 2021, Cumartesi, 12:07
Bilgi: Haber Kaynağı: Çeşitli Haber Siteleri
Identification of and Surveillance for the SARS-CoV-2 Variants B.1.427 and B.1.429 - Colorado, January-March 2021
On January 24, the Colorado Department of Public Health and Environment (CDPHE) identified the first Colorado case of COVID-19 attributed to the B.1.427 and B.1.429 variants. To improve convenience sampling to identify and track emerging variants, CDPHE established a 30-site statewide sentinel surveillance system.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421658
Etiketler:

EklenmeTarihi: 20 Kasım 2021, Cumartesi, 12:07
Bilgi: Haber Kaynağı: Çeşitli Haber Siteleri
Anxiety-Related Adverse Event Clusters After Janssen COVID-19 Vaccination - Five U.S. Mass Vaccination Sites, April 2021
Five mass vaccination sites reported 64 anxiety-related events, including 17 events of syncope (fainting) after receipt of Janssen COVID-19 vaccine. The reporting rates of syncope to VAERS after Janssen COVID-19 and influenza vaccines (2019-20) were 8.2 and 0.05 per 100,000 doses, respectively.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421542
Etiketler:

EklenmeTarihi: 20 Kasım 2021, Cumartesi, 12:07
Bilgi: Haber Kaynağı: Çeşitli Haber Siteleri
Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021
Nearly 8 million doses of the Janssen COVID-19 vaccine had been administered. Review of safety monitoring data found that 97% of reported reactions after vaccine receipt were nonserious, consistent with preauthorization clinical trials data. A total of 17 thrombotic events with thrombocytopenia were detected, including three non-CVST events.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421539
Etiketler:

EklenmeTarihi: 20 Kasım 2021, Cumartesi, 12:07
Bilgi: Haber Kaynağı: Çeşitli Haber Siteleri
Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021
mRNA COVID-19 vaccine effectiveness against SARS-CoV-2 infection was 90% for full immunization (≥14 days after second dose) and 80% for partial immunization (≥14 days after first dose but before second dose) in real-world conditions.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=419354
Etiketler:

EklenmeTarihi: 20 Kasım 2021, Cumartesi, 12:07
Bilgi: Haber Kaynağı: Çeşitli Haber Siteleri
Symptoms of Anxiety or Depressive Disorder and Use of Mental Health Care Among Adults During the COVID-19 Pandemic - United States, August 2020-February 2021
From August 2020-February 2021, adults with recent symptoms of an anxiety or depressive disorder increased from 36% to 42%. Increases were largest among adults 18-29 years and those with less than a high school education.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=419353
Etiketler:

EklenmeTarihi: 20 Kasım 2021, Cumartesi, 12:07
Bilgi: Haber Kaynağı: Çeşitli Haber Siteleri
Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years - United States, January-March 2021
In U.S. hospitals during January-March 2021, receipt of Pfizer-BioNTech or Moderna COVID-19 vaccines was 94% effective against COVID-19 hospitalization among fully vaccinated adults and 64% effective among partially vaccinated adults aged ≥65 years.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421438
Etiketler:

EklenmeTarihi: 20 Kasım 2021, Cumartesi, 12:07
Bilgi: Haber Kaynağı: Çeşitli Haber Siteleri
Linked Clusters of SARS-CoV-2 Variant B.1.351 - Maryland, January-February 2021
This report describes an investigation in Maryland of two linked clusters of COVID-19 cases identified as the B.1.351 variant.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421458
Etiketler:

EklenmeTarihi: 20 Kasım 2021, Cumartesi, 12:07
Bilgi: Haber Kaynağı: Çeşitli Haber Siteleri
Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients - United States, April 2021
The Advisory Committee on Immunization Practices concluded that the benefits of resuming Janssen COVID-19 vaccination among persons aged ≥18 years outweighed the risks and reaffirmed its interim recommendation under FDA's Emergency Use Authorization, which includes a new warning for rare clotting events among women aged 18-49 years.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=421416
Etiketler:

EklenmeTarihi: 20 Kasım 2021, Cumartesi, 12:07
Bilgi: Haber Kaynağı: Çeşitli Haber Siteleri
Postvaccination SARS-CoV-2 Infections Among Skilled Nursing Facility Residents and Staff Members - Chicago, Illinois, December 2020-March 2021
Twenty-two possible breakthrough SARS-CoV-2 infections occurred among fully vaccinated persons ≥14 days after their second dose of COVID-19 vaccine. Two thirds of persons were asymptomatic. A minority of persons with breakthrough infection experienced mild to moderate COVID-19-like symptoms; two COVID-19-related hospitalizations and one death occurred. No facility-associated secondary transmission was identified.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=420772
Etiketler:

EklenmeTarihi: 20 Kasım 2021, Cumartesi, 12:07
Bilgi: Haber Kaynağı: Çeşitli Haber Siteleri
Rapid Scale-up of an Antiretroviral Therapy Program Before and During the COVID-19 Pandemic - Nine States, Nigeria, March 31, 2019-September 30, 2020
This report describes a program that increased the number of persons with HIV infections who initiated antiretroviral therapy before and during the COVID-19 pandemic.
https://tools.cdc.gov/api/embed/downloader/download.asp?m=342778&c=418930
Etiketler: